ICDD is a biotech company dedicated to identifying molecular determinants of pre-dementia stages of neurodegenerative diseases. ICDD develops immunoanalyses using proprietary technologies based on pertinent proteins identified by cellulomic and proteomic.
More precise, readily available, and less expensive tests for Alzheimer's disease.
In Alzheimer's disease, identification of pre-dementia stages is crucial to enable stratification of patients most likely to benefit from drugs currently being developed to limit or block disease progression. ICDD is developing the ADFlag® blood diagnostic test, which has already been validated in two independent cohorts totaling about 300 patients across several clinical sites in Europe, such as those in the Pharmacog consortium.
Recent clinical data with solanezumab demonstrate that earlier recruitment may facilitate the demonstration of therapeutic efficacy in disease-modifying drugs. Markers such as those developed by ICDD go beyond the recognition of prodromal AD and avoid the risks associated to spinal taps. Contact us to integrate ADFlag® measurements into your clinical trials.
Our pipeline also includes immunoanalyses capable of segregating early signs of AD versus other neurodegenerative diseases. Indeed, differential diagnosis is currently difficut to make with existing solutions.
This line of product is developed in collaboration with the Danish Neurodegeneration Center and Lundbeck.
Individual people with Parkinson's need individualized treatment and care.
ICDD operates patient-derived translatable models to select disease-modifying drugs in specific Parkinson's subpopulations. These models are developed in collaboration with the Michael J. Fox Foundation. Homogeneous subgroups, such as Lrrk2+ patients, may respond differently to different drugs.
In order to adress the current unmet medical need in Parkinson's, ICDD partners with you to identify the molecular determinants for therapeutic response to your drug.
Improving care through companion diagnostics.
There is no diagnostic disease in Huntington's disease as it is a genetic disease. However there are no correlations between disease severity and the extent of the CAG repeats in the Huntingtin gene.
It is necessary to identify molecular response elements to drugs shown to reverse the disease phenotype in patient-derived translatable disease model, such as those developed by ICDD.
ICDD focuses on facilitating drug development in neurodegeneration by providing cell-based models for disease modifying drug selection, OMICS technology platforms for biomarker discovery and state-of-the-art bioinformatics modeling capabilities.
Technologies developed by ICDD focus on pathophysiological mechanisms associated with neurodegeneration, such as inflammation, mitochondrial impairment, and cytoskeleton dynamics.
Latest news and advances
ICDD presented the poster "Alzheimer’s Disease: Risk factors and Biomarkers" at the SfN's 2015 annual meeting to show the clinical demonstration for the stratification performances in pre-dementia AD patients of its blood diagnostic marker ADFlag®.
ICDD's ADFlag® panel was validated through local and international collaboration with expert Alzheimer's disease centers, confirming the initial 147 patients in a larger multi-centric trial in the Pharmacog consortium.
The Michael J. Fox Foundation supports ICDD for it's Parkinson's disease models and marker development, notably in identifying new targets for Lrrk2 Parkinsonism.